Cassius Mining Limited logo

Cassius Mining Limited (CMD)

Market Open
ASX ASX
ASX ASX Primary
OTC PINK OTC PINK CXA CXA
3.79M Market Cap
- P/E Ratio
- Div Yield
149,305 Volume
- Eps
Want to track CMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

CMD is not paying dividends to its shareholders.
The last earnings report, released on Nov 22, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Cassius Mining Limited has completed 2 stock splits, with the recent split occurring on Nov 17, 2017.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on ASX (AUD).

Cassius Mining Limited (CMD) FAQ

On which exchange is it traded?

Cassius Mining Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is CMD.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 3.79M.

Has Cassius Mining Limited ever had a stock split?

Cassius Mining Limited had 2 splits and the recent split was on Nov 17, 2017.

Cassius Mining Limited Profile

Biotechnology Industry
Healthcare Sector
Ms. Tine Kold Olesen Ph.D. CEO
ASX Exchange
Q2144K100 CUSIP
Sweden Country
2 Employees
- Last Dividend
22 May 2008 Last Split
- IPO Date

Overview

Biosergen AB is a biotechnology company based in Solna, Sweden, with foundations laid in 2004. The company specializes in the development of antifungal products, focusing on novel solutions for the treatment of various fungal infections. Operating within the biotech industry, Biosergen AB leverages scientific research to address the growing need for effective antifungal therapies, particularly in a world where resistance to existing treatments is on the rise.

Products and Services

  • BSG005

    • This is Biosergen AB’s forefront antifungal drug candidate, designed to combat fungal infections effectively. The development of BSG005 represents the company's commitment to introducing novel treatments into the market, targeting a range of fungal pathogens that cause serious illnesses. By focusing on this drug, Biosergen AB aims to provide a groundbreaking solution to improve patient outcomes in the realm of antifungal therapy.

Contact Information

Address: Fogdevreten 2
Phone: 46 4 52 08 02 470
Download app banner
Blog Affiliate Program About Terms Privacy Help Contact Us
2026 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark